Dr. Julien is professor in the department of psychiatry and neuroscience at Université Laval in Canada and director of axis integrative neuroscience and experimental therapies at the CERVO Brain Research Centre. He obtained a PhD in Biochemistry from McGill University and then completed a postdoctoral fellowship in Molecular Genetics at the National Institute of Medical Research in London UK. From 1989 to 2003, he was a professor in the Department of Neurology and Neurosurgery at McGill University. Since 2003, he holds a Canada Research Chair in Neurodegeneration at Université Laval. He received several distinctions including the Sheila Essey Award from the American Academy of Neurology, the Prix Léo-Pariseau for medical sciences, the Jonas Salk award from March of Dimes Canada, Fellow of the Canadian Academy of Health Sciences and Fellow of the Royal Society of Canada. Jean-Pierre Julien is a world leader in the field of neurodegenerative disorders, especially amyotrophic lateral sclerosis (ALS). Through innovative mouse genetic and pharmacological approaches, he has made landmark discoveries on pathogenesis of ALS and discovered new therapeutic targets. He has pioneered the development of novel experimental treatments for ALS such as immunotherapies to reduce abnormal protein misfolding and natural product-based therapeutics to target the neuroinflammatory pathway.